High dose ranolazine formulations
AssigneeSyntex (U.S.A.) Inc.
InventorsGlenn J. Samuels, Jung-Chung Lee, Charles Lee, Stephen Berry, Paul J. Jarosz
Life of this patent
Estimating the term…
Abstract
Mycophenolate mofetil, mycophenolic acid, and ranolazine can be conveniently manufactured into high dose oral formulations by the hot melt filling of a supercooled mycophenolate mofetil, mycophenolic acid, or ranolazine liquid into a pharmaceutical dosage form. High dose oral pharmaceutical formulations and manufacturing methods therefor are disclosed.
Claims12
A pharmaceutical formulation comprising a therapeutically effective amount of ranolazine, said ranolazine having been heated to a first temperature above its melting point, cooled to a second temperature below its melting point at which second temperature said ranolazine remained liquefied, and filled into a pharmaceutical dosage form while in said cooled liquefied state.
A method for manufacturing a pharmaceutical formulation of ranolazine, comprising the steps of:
- liquefying the ranolazine by heating it to a first temperature above its melting point;
- cooling said liquefied ranolazine to a second temperature below its melting point, at which second temperature said ranolazine remains liquefied;
- and
- filling said cooled liquefied ranolazine into a pharmaceutical dosage form.
Dependencies are inferred from the claim text.